Dave Levitan

A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.

Women who receive two doses of HPV vaccine have higher prophylactic efficacy than women who receive only one dose, according to a database study.

The use of sentinel lymph node biopsy alone in women with early cervical cancer resulted in less surgical morbidity without a significant increase in the risk of recurrence, according to a new prospective study.

Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.

Treating women with stage IVB cervical cancer with whole pelvic radiation along with standard chemotherapy improved survival over chemotherapy alone in a retrospective study.

A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.

The final, long-term analysis of the landmark IRIS study showed that imatinib’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed.

Sorafenib, gemcitabine, and cisplatin had promising activity and was well tolerated in patients with muscle-invasive urothelial bladder cancer.

Survivors of childhood Ewing sarcoma have substantial risk for late mortality and subsequent neoplasms, according to a long-term follow-up study.

A mathematical approach revealed a set of criteria that could help define prostate cancer patients with poor prognosis, according to a new analysis. This could help many patients avoid overtreatment.

In patients with breast cancer with a recurrence score based on a 21-gene expression assay of 11 to 25, outcomes were similar whether chemotherapy was used or not.

Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses.

Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia.

The LUX-Lung 7 trial found no significant differences between afatinib and gefitinib for patients with EGFR mutation–positive stage IIIb/IV NSCLC.

Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens.

A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.

Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.

Though it is used infrequently, lymph node dissection with higher yield of lymph nodes is associated with lower all-cause mortality among patients with urothelial carcinoma of the upper urinary tract who undergo nephroureterectomy.

A genomic analysis of Ewing sarcoma found substantial epigenetic heterogeneity both between tumors and within tumors, highlighting the need to consider non-genetic aspects in cancer biology and treatment.

A long-term study found that adding 24 months of antiandrogen therapy with bicalutamide to salvage radiation therapy increased overall survival and prostate cancer–specific survival compared with placebo in men who underwent radical prostatectomy.

Intentional weight loss can lower the risk of endometrial cancer in postmenopausal women, according to a new study. This was especially true of obese women who lost weight.

A study examining predictors of outcome following relapse of primary retroperitoneal sarcoma found that time to local recurrence or distant metastasis significantly predict survival, and that patients who undergo resection for the recurrent disease have better survival than others.

A phase I trial found that ONT-380 had a lower incidence of certain adverse events associated with this class of agent and notable anti-tumor activity in heavily pretreated metastatic HER2-positive breast cancer patients.

A large registry study found that certain breast cancer patients gain a significant survival benefit with breast conserving surgery plus radiation therapy compared with mastectomy.

Residual cancer burden was found to be prognostic for long-term survival following neoadjuvant chemotherapy for three phenotypic subsets of breast cancer in a new single-institution study.

The PD-1 inhibitor pembrolizumab yielded significantly improved overall survival vs chemotherapy as second-line treatment in advanced urothelial cancer.

The use of multi-parametric magnetic resonance imaging could allow more than a quarter of men with high prostate-specific antigen levels to avoid undergoing transrectal ultrasound-guided prostate biopsy.

CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor.

The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer.